{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T10:03:17Z","timestamp":1791453797610,"version":"4.3.3"},"reference-count":6,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jcf.2023.10.008","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T01:32:13Z","timestamp":1697160733000},"page":"366-367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Elexacaftor\/Tezacaftor\/Ivacaftor therapy in cystic fibrosis children previously CFSPID: Is it over-medicalization?"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1106-4424","authenticated-orcid":false,"given":"V.","family":"Terlizzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2023.10.008_bib0001","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jcf.2020.11.006","article-title":"Updated guidance on the management of children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome\/cystic fibrosis screen positive, inconclusive diagnosis (CRMS\/CFSPID)","volume":"20","author":"Barben","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.10.008_bib0002","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcf.2022.10.002","article-title":"Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis","volume":"22","author":"Southern","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.10.008_bib0003","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jcf.2023.04.018","article-title":"Variability of the sweat test in children with cystic fibrosis previously CRMS\/CFSPID: a retrospective monocenter experience","volume":"22","author":"Terlizzi","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.10.008_bib0004","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1164\/rccm.200901-0069OC","article-title":"Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening","volume":"180","author":"Sly","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2023.10.008_bib0005","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1513\/AnnalsATS.202201-024OC","article-title":"Cystic fibrosis screen positive, inconclusive diagnosis genotypes in people with cystic fibrosis from the U.S. patient registry","volume":"20","author":"Salinas","year":"2023","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2023.10.008_bib0006","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jcf.2022.04.020","article-title":"Clinical outcomes of a large cohort of individuals with the F508del\/5T; TG12 CFTR genotype","volume":"21","author":"Tosco","year":"2022","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932300927X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932300927X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T08:24:03Z","timestamp":1772353443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156919932300927X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":6,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S156919932300927X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.10.008","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elexacaftor\/Tezacaftor\/Ivacaftor therapy in cystic fibrosis children previously CFSPID: Is it over-medicalization?","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}